KPV is a three-amino-acid fragment derived from alpha-melanocyte-stimulating hormone. Anti-inflammatory findings come from laboratory and animal models. The reviewed source set contains no published human clinical trial establishing safety or benefit.
Research peptide
KPV
KPV is a three-amino-acid fragment derived from alpha-melanocyte-stimulating hormone. Anti-inflammatory findings come from laboratory and animal models. The reviewed source set contains no published human clinical trial establishing safety or benefit.
Regulatory watch
Last reviewed Jul 12, 2026
Next review Jul 24, 2026
Evidence snapshot
Mechanism research: KPV is an alpha-MSH-derived tripeptide studied for anti-inflammatory activity.
Evidence level: published findings are limited to laboratory and animal models.
Human evidence: no published clinical trial was identified in the reviewed source set.
Regulatory status: KPV is not FDA-approved and was scheduled for FDA advisory committee discussion in July 2026.
Research record
What the evidence record says
- Evidence grade
- Not Graded
- Regulatory status
- KPV regulatory status has not been fully reviewed by Peptide Report editorial team. See company profiles and regulatory watch for current status.
Evidence records
Studies, registries, reviews, and regulatory records
Evidence review pending
- Detailed evidence review for KPV is pending editorial assessment. Current summary reflects available public records.
Records: FDA compounding advisory committee July 2026: peptides, FDA BPC-157 compounding safety risk: immunogenicity, KPV and alpha-MSH-derived tripeptides: anti-inflammatory activity in preclinical models
Evidence timeline
What changed, and when
Peptide Report last reviewed KPV on 2026-07-12.
Records: FDA compounding advisory committee July 2026: peptides
Direct answers
Frequently asked questions
What is KPV?
KPV is a research peptide tracked by Peptide Report. See the full profile for current editorial assessment.
Open research questions
What is still unknown
- What is the complete human evidence base for KPV?
- What are the long-term safety considerations for KPV?
Tracked claims
KPV is in the July 2026 FDA peptide discussion queue.
Evidence level: Primary regulatory
Sources: FDA compounding advisory committee July 2026: peptides
How to read this: Committee review is part of a policy process and does not establish clinical benefit.
Preclinical studies report that KPV has anti-inflammatory effects in animal models, but no human clinical trials have been published.
Evidence level: Peer reviewed
Sources: KPV and alpha-MSH-derived tripeptides: anti-inflammatory activity in preclinical models
How to read this: KPV is a tripeptide derived from alpha-MSH. The reviewed evidence is preclinical and cannot establish treatment effects in humans.
KPV is discussed online as an oral anti-inflammatory peptide despite the lack of human clinical evidence.
Evidence level: Community discussion
Sources: KPV and alpha-MSH-derived tripeptides: anti-inflammatory activity in preclinical models, FDA BPC-157 compounding safety risk: immunogenicity
How to read this: Online treatment claims exceed the reviewed human evidence. FDA compounding records address a separate regulatory question.
Linked public records
Regulatory actions involving KPV
FDA advisory committee to review seven peptide-related bulk drug substances
Scheduled · Scheduled public meeting
FDA scheduled a two-day Pharmacy Compounding Advisory Committee meeting to discuss whether BPC-157, KPV, TB-500, MOTS-c, emideltide/DSIP, Semax, and Epitalon-related substances should be included on the 503A Bulks List. The committee provides advice; the meeting itself is not a final agency determination.
Compounds: BPC-157, KPV, TB-500, MOTS-c, DSIP, Semax, Epitalon
Free report
Get the source-quality checklist
Use the same checklist Peptide Report uses to separate KPV claims, source records, supplier documentation, and media signals.
V1 collects email, role, and topic interest only. No medication, health-condition, dosing, or current-use data is collected in this form.
Formspree processes this submission for Peptide Report. Privacy notice.
Sources on this page
Each source record is linked to the claim or evidence note it supports.
July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting
FDA Pharmacy Compounding Advisory Committee meeting notice for July 23 to 24, 2026, scheduling peptide bulk substances for discussion.
23 linked pagesOpen original ·
fda-pcac-july-2026Certain bulk drug substances for use in compounding may present significant safety risks
FDA risk page lists BPC-157: compounded BPC-157 may pose immunogenicity risk and peptide-related impurity concerns for certain routes of administration.
41 linked pagesOpen original ·
fda-bulk-risk-listKPV and alpha-MSH-derived tripeptides: anti-inflammatory activity in preclinical models
Preclinical studies of KPV (Lys-Pro-Val), a tripeptide derived from alpha-melanocyte-stimulating hormone (alpha-MSH), showing anti-inflammatory effects in animal models of intestinal and systemic inflammation. No human clinical trials have been published.
5 linked pagesOpen original ·
pubmed-kpv-anti-inflammatoryRelated compounds
BPC-157
BPC-157 is an experimental peptide with extensive animal research but very limited human evidence. A Phase 1 registry re...
Regulatory watchDSIP
Delta sleep-inducing peptide, or DSIP, was studied in small human sleep experiments during the 1970s and 1980s. Results ...
Regulatory watchEpitalon
Epitalon is a synthetic tetrapeptide promoted for longevity and telomere-related effects. The reviewed evidence rests la...
Regulatory watchSemax
Semax is a synthetic ACTH-derived peptide registered as a medicine in Russia. Cognitive and attention claims rely mainly...
Regulatory watchStay informed